Australian Biotechnology News
Latest stories
  • +

    New protein points to possible Alzheimer’s cure 02/09/2010 18:22:00

    Discovery indicates potential for new drugs that suppress beta amyloid without affecting other functions
    An 84-year old American Nobel Laureate has discovered a new protein which observers are saying may herald a completely new approach to treating Alzheimer’s disease.
  • +

    Feature: Diagnosing Darwin 01/09/2010 17:14:00

    For much of his life, Charles Darwin lived with a mysterious illness that caused bouts of intense nausea and vomiting. Now Melbourne pathologist, Dr John Hayman, has a theory as to the cause of this strange disorder.
    In January last year, Dr John Hayman read a biography of Charles Darwin and became intrigued by Darwin’s almost lifelong battle with a chronic, relapsing illness. But now, Hayman, an Associate Professor in Monash University’s Department of Pathology, thinks he’s narrowed it down to a rare mitochondrial disorder inherited from his mother.
  • +

    Halcygen reports maiden profit 01/09/2010 18:09:00

    Acquisition of Mayne Pharma a major factor in reversing the previous year’s loss
    Antibiotic developer Halcygen Pharmaceuticals today reported a maiden net profit of $3.25 million for the year ended June 30, 2010, largely driven by the company’s acquisition of Mayne Pharma International late last year from Hospira Inc.
  • +

    Bionomics anxiety drug could be more effective than valium 31/08/2010 00:16:00

    Study results show BNC210 more effective in treating stressed rats with Phase Ib trials scheduled for later this year
    Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem).
  • +

    Argy-bargy continues at Avexa 27/08/2010 15:28:00

    Major shareholder Calzada calls for EGM in September
    Troubled HIV drug developer Avexa may be poised for yet another coup after major shareholder Caldaza this week called for an extraordinary general meeting to discuss the future of the company
  • +

    Under-arm license delivers maiden FY profit for Acrux 27/08/2010 14:46:00

    FDA approval of Axiron could see shareholders receiving dividends by next year
    Testosterone booster Acrux this week stormed into the black for the first time, announcing a net profit of $46.6 million after earlier in the year signing one of the biggest ever multinational licensing deals for an Australian biotech.
More >AgBiotech
  • +

    SA scientist pioneers new system for organic waste 17/06/2010 22:58:00

    Conversion of organic waste into feedstock, energy and irrigation water.
    A biotechnologist from the South Australian Research and Development Institute ( SARDI ) has demonstrated a unique ‘waste-food-chain’ with major implications for industries that product organic waste.
  • +

    Government announces $440,000 to bolster overseas collaborations 08/06/2010 13:30:00

    Study into octopus venom for pain and cancer among 69 programs to receive new funding
    The federal government has announced new funding of $440,000 to support 69 research collaborations between Australian and overseas groups, as part of the International Science Linkages – Science Academies Program.
More >Biomedical
  • +

    Bionomics anxiety drug could be more effective than valium 31/08/2010 00:16:00

    Study results show BNC210 more effective in treating stressed rats with Phase Ib trials scheduled for later this year
    Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem).
  • +

    Argy-bargy continues at Avexa 27/08/2010 15:28:00

    Major shareholder Calzada calls for EGM in September
    Troubled HIV drug developer Avexa may be poised for yet another coup after major shareholder Caldaza this week called for an extraordinary general meeting to discuss the future of the company
More >Bioinformatics
  • +

    Bionomics anxiety drug could be more effective than valium 31/08/2010 00:16:00

    Study results show BNC210 more effective in treating stressed rats with Phase Ib trials scheduled for later this year
    Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem).
  • +

    Feature: Next next generation sequencing 26/08/2010 12:33:00

    Technological advances in the field of genome sequencing are overcoming cost and speed limitations and opening the door to new applications, with third generation genome sequencers just around the corner.
    It took nearly two decades to go from the release of the first semi-automated genome sequencer in the mid-1980s to the launch of Roche's flagship 454 FLX next generation sequencer in 2005. The 454 is now one of three major players in the next gen market whose impact on the world of genomics cannot be underestimated. Just five years later we are poised to embrace another new wave of sequencing technology.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
Subscribe now!
 
Jobs